Inozyme Pharma
68 articles with Inozyme Pharma
-
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
12/1/2022
Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on Thursday, December 8, 2022, from 8:00-8:30am ET.
-
Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates
11/10/2022
Inozyme Pharma, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided recent business highlights.
-
Inozyme Pharma to Participate in Upcoming Investor Conferences
11/7/2022
Inozyme Pharma, Inc. today announced that Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the following investor conferences.
-
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
11/3/2022
Inozyme Pharma, Inc. today announced the first self-administration of INZ-701 in the open-label Phase 2 extension portion of the ongoing Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency.
-
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database
10/31/2022
Inozyme Pharma, Inc. (Nasdaq: INZY) today announced the publication of an article titled, “ENPP1 Deficiency: A clinical update on the relevance of individual variants using a locus-specific database,” in Human Mutation.
-
Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates
8/15/2022
Inozyme Pharma, Inc. today reported financial results for the second quarter ended June 30, 2022 and provided recent business highlights.
-
Philanthropic Donations and Debt Financings Rake in Cash for Cancer, Alzheimer's and Mental Healt...
7/29/2022
Money on the Move: A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases -
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
7/26/2022
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that it has entered into a debt financing facility for up to $70 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
-
Prometheus completed its Phase II trial in UC, Algernon announced its Phase II trial of IPF and chronic coffee, Seelos dosed the first patient of SLS-005 for patients with ALS.
-
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)
7/19/2022
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects treated in the Phase 1.
-
Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases
6/16/2022
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, announced a partnership with Rady Children’s Institute for Genomic Medicine to advance and evaluate a novel newborn screening technology to facilitate diagnosis of genetic diseases.
-
Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.
-
Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer
6/7/2022
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer.
-
Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference
6/1/2022
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the Jefferies Healthcare Conference.
-
Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights
5/10/2022
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.
-
Inozyme Pharma to Present at Upcoming Investor Conferences - May 03, 2022
5/3/2022
Inozyme Pharma, Inc. announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the following investor conferences:
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market
4/14/2022
Inozyme Pharma, Inc. today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock.
-
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency
4/12/2022
Inozyme Pharma, Inc. today announced that the first patient has been dosed in its Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency and the second cohort in the ongoing Phase 1/2 clinical trial in ENPP1 Deficiency has been fully enrolled.